Analysis of:
FDA Adviser Questions Surrogate Endpoints for Diabetes Drug Approvals (www.medpagetoday.com)
To demand diabetes medications have positive outcomes would be akin to asking for proof that antibiotics save lives or statins lower blood sugars. If this be law, we would have very few drugs and lots of sick patients.
Analysis of:
New Data Highlights Long Term Tolerability and Sustained Benefits of the Exelon Patch in the Treatment of Alzheimer’s Disease (pharmalive.com)
Exelon is an excellent drug for the stablization of cognitive decline in Alzheimer's disease. It's use has been limited by its GI side effects. It has a unique mechanism of actioncompared to other drugs on the market. The availabilty of a transdermal deliviery system will permit much broader use...
Analysis of:
GlaxoSmithKline updates prescribing information for Avandia in the US (www.pipelinereview.com)
The Black Box CHF Warning for Avandia and Actos, is not new information. It merely defects the real issue-- the risk of overall cardiac events.
Analysis of:
Framingham Observational Study Notes Greater Incidence Of Metabolic Syndrome Among Adults Consuming Soft Drinks (www.medicalnewstoday.com)
People, in general, who may have other concerns than their health, consume soft drinks, both regular and diet. High fructose corn syrup in our society is like lead to the Romans. Why is taking our government so long to figure this out?
August 13, 2007not always
Analysis of:
Older and cheaper pills just fine for diabetes (www.reuters.com)
1-diabetics are an extremely diverse group of people 2-co-morbidities, stage of disease, and the pancreatic reserve all govern the ideal regimen for a certain patient 3-the more options we have, the better equipped we are to help more patients 4-glycemic control is not the only decisive factor when...
Analysis of:
Bristol-Myers Drug, First in New Family, Controls Blood Sugar (www.bloomberg.com)
Dapagliflozin has a long way to go to prove its efficacy and safety as a potential diabetes medication. However, innovative medications are welcome as they will be pieces of the diabetic solution puzzle.
Analysis of:
Older and cheaper pills just fine for diabetes (www.reuters.com)
Given that obesity is one of the prime causes of type II diabetes, and that an important part of the patient's treatment should be directed to weight loss which improves insulin resistance, I feel that prescribing drugs that you know will cause the patient to fail at losing weight are counterproductive. ...
Analysis of:
Small Physician Practices Struggle With Profitability (www.prnewswire.com)
Many doctors are taking patients off of this drug after the NEJM article and ADA symposium. This brings out many concerning facts about this drug and its history. First, that this data was known years ago and not made public by GSK. Second, that there is little reason now to treat patients with...
Analysis of:
Galvus(R), a new oral treatment for type 2 diabetes, receives positive opinion recommending European Union approval (www.pipelinereview.com)
Galvus does not seem to have a competitive edge over Januvia, its main competition. Galvus needs to demonstrate a yet unknown significant advantage to gain significant market share.